These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 9093323

  • 1. Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn.
    Pediatrics; 1997 Apr; 99(4):645-50. PubMed ID: 9093323
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
    Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
    [Abstract] [Full Text] [Related]

  • 5. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR, Simoes EA, Hemming VG.
    Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741
    [Abstract] [Full Text] [Related]

  • 6. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group.
    Pediatrics; 1997 Jan; 99(1):93-9. PubMed ID: 8989345
    [Abstract] [Full Text] [Related]

  • 7. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [Abstract] [Full Text] [Related]

  • 8. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.
    Committee on Infectious Diseases.
    Pediatrics; 2009 Dec; 124(6):1694-701. PubMed ID: 19736258
    [Abstract] [Full Text] [Related]

  • 9. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 10. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
    Groothuis JR, Hoopes JM, Hemming VG.
    Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
    [Abstract] [Full Text] [Related]

  • 11. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC.
    N Engl J Med; 1993 Nov 18; 329(21):1524-30. PubMed ID: 8413475
    [Abstract] [Full Text] [Related]

  • 12. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group.
    Simoes EA, Sondheimer HM, Top FH, Meissner HC, Welliver RC, Kramer AA, Groothuis JR.
    J Pediatr; 1998 Oct 18; 133(4):492-9. PubMed ID: 9787686
    [Abstract] [Full Text] [Related]

  • 13. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B, Steele S, Janes M, Pinelli J.
    Curr Med Res Opin; 2009 Jul 18; 25(7):1585-91. PubMed ID: 19469698
    [Abstract] [Full Text] [Related]

  • 14. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA, Cosgrove JF, MacMahon P.
    Ir Med J; 2000 Dec 18; 93(9):284. PubMed ID: 11209917
    [Abstract] [Full Text] [Related]

  • 15. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    Meissner HC, Long SS, American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec 18; 112(6 Pt 1):1447-52. PubMed ID: 14654628
    [Abstract] [Full Text] [Related]

  • 16. Palivizumab for respiratory syncytial virus prophylaxis.
    Sandritter T.
    J Pediatr Health Care; 1999 Dec 18; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
    [Abstract] [Full Text] [Related]

  • 17. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
    Rodriguez WJ, Gruber WC, Welliver RC, Groothuis JR, Simoes EA, Meissner HC, Hemming VG, Hall CB, Lepow ML, Rosas AJ, Robertsen C, Kramer AA.
    Pediatrics; 1997 Mar 18; 99(3):454-61. PubMed ID: 9041304
    [Abstract] [Full Text] [Related]

  • 18. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
    Simoes EA, Carbonell-Estrany X.
    Pediatr Infect Dis J; 2003 Feb 18; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
    [Abstract] [Full Text] [Related]

  • 19. Respiratory syncytial virus immune globulin intravenous.
    Wandstrat TL.
    Ann Pharmacother; 1997 Jan 18; 31(1):83-8. PubMed ID: 8997472
    [Abstract] [Full Text] [Related]

  • 20. Prevention of respiratory syncytial virus infection in high risk infants.
    Prince AM, Jacobs RF.
    J Ark Med Soc; 2001 Oct 18; 98(4):115-8. PubMed ID: 11594047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.